科學+家 結晶研究霜劑 | SCIENTIST HOME Crystallized Study Cream 60ml

crystal_c
HK$280.00
In stock
1
Product Details
品牌 Brand: BioSci

尿酸結晶

在過去的幾十年裏,發達國家的高尿酸血症和痛風的患病率都在上升,因此痛風的負擔也在新增。高尿酸血症和痛風與心血管问题的關係以及高尿酸血症干預進一步獲益的機會最近在文獻中被強調。

成像技術已被證明可用於檢測尿酸鹽沉積,甚至在出現第一個臨床症狀之前,就能夠評估沉積程度並在降尿酸治療期間提供晶體消耗的客觀測量。

因此,針對疾病負擔的不同階段和治療的不同階段,建議了不同的靶點。

最終的戰略目標是完全溶解組織中的尿酸鹽晶體,從而避免肌肉骨骼結構的進一步症狀和結構損傷。

總之,有證據表明,早期治療痛風和相關的共病是可取的,新的成像科技可能有助於評估特定患者的沉積負擔和對降低尿酸治療的反應。最後,痛風患者醫療保健的最終戰略目標是完全分解尿酸鹽晶體沉積。

Ref: Fernando Perez-Ruiz 1 , Nicola Dalbeth, Tomas Bardin A review of uric acid, crystal deposition disease, and gout. Review Adv Ther . 2015 Jan;32(1):31-41. doi: 10.1007/s12325-014-0175-z. Epub 2014 Dec 23. PMID: 25533440 PMCID: PMC4311063 DOI: 10.1007/s12325-014-0175-z

科學+家 結晶研究霜劑

可能適合多學科復康調理:

  • 減輕尿酸鈉炎症 (1)
  • 高尿酸炎症的改善 (2)
  • 尿酸肾结石 (3)
  • 痛風性關節炎 (4)
  • 高尿酸心血管 (5)
  • 尿酸結締鈣化 (6)
  • 尿酸鈉冠狀動脈鈣化 (7)
  • 焦磷酸鈣結晶溶解 (8)
  • 溶解草酸鈣結晶 (9)

不適合人士:關節已嚴重變形,甚或已致殘

使用方法:每天3至5次,外塗於有需要的關節位置

生活配合戒口高嘌嚀食品飲料及少吃煎炸烤燒食物,多休息,多喝水

過程可能:5至10天左右,關節開始感受到略有鬆弛

使用週期:

  • 療程約1-3個月,視乎優化情况,極理想優化後可停用
  • 試用2星期沒出現值得鼓舞現象,請停用,建議繼續尋求醫生處理
碳酸氫鉀副作用:

  • 如果出現過敏或不良反應,請停止服用,並立即就醫。

注意:

  • 本品為外塗補充品,不能代替藥物
  • 對碳酸氫鉀過敏者不適用
  • 如有不適反應,建議停止使用
  • 如不瞭解問題原因或問題持續,請儘快諮詢醫生

成份:潤膚霜、 軟骨素硫酸鹽(1)、植物皂甙、根提取物、檸檬酸鉀(2)、枸櫞酸三鉀、碳酸氫鉀、綠原酸、咖啡單寧酸、毗黎勒果提取物(3)、L-聚天冬氨酸鈉鹽、辛烷磺酸鈉、三聚磷酸鈉、多磷酸鈉

規格型號: 60毫升/霜劑/瓶裝
儲存方法:請存放在陰涼乾燥處

原產地:中國香港

如你有任何疾病, 請遵照閣下醫生的完整醫療方案; 而是否使用多學科復康方案前, 你必須咨詢主診醫生的意見, 如果閣下的主診醫生不建議您加入補充劑調理組合, 請你不要使用。如果你需要尋求其他醫生作第二咨詢, 閣下可聯絡我們線上<無邊界醫生>或你自己城市內的其他專業醫生的再診斷。

__


Uric Acid Crystal

The prevalence of both hyperuricemia and gout has risen in the last decades in developed countries and therefore the burden of gout has increased. The association of hyperuricemia and gout with cardiovascular outcomes and the opportunity of further benefits of intervention on hyperuricemia have been recently highlighted in the literature.

Imaging techniques have proven to be useful for detection of urate deposition, even prior to the first clinical symptoms, enabling the evaluation of the extent of deposition and providing objective measurement of crystal depletion during urate-lowering treatment.

Treating to target is increasingly used as the approach to treatment of diverse diseases. Therefore, different targets have been recommended for different stages of the burden of disease and for different stages of treatment.

The final strategic target, to which any effort should be taken into consideration, is to completely dissolve urate crystals in tissues and therefore avoid further symptoms and structural damage of involved musculoskeletal structures.

In summary, evidence suggest that an early approach to the treatment of gout and associated comorbidities is advisable, that new imaging techniques may help to evaluate both the burden of deposition and response to urate-lowering treatment in selected patients, and finally that the final strategic objective of healthcare for patients with gout is to completely resolve urate crystal deposits.

Ref: Fernando, Perez-Ruiz 1 ,Nicola Dalbeth, Tomas Bardin. A review of uric acid, crystal deposition disease, and gout. Review Adv Ther. 2015 Jan;32(1):31-41. doi:10.1007/s12325-014-0175-z. Epub 2014 Dec 23. PMID: 25533440 PMCID: PMC4311063


SCIENTIST HOME CRYSTALLIZED STUDY CREAM

Suggested multidisciplinary rehabilitation:

  • Reduce sodium urate inflammation (1)
  • Improvement in hyperuricemia and inflammation (2)
  • Uric acid kidney stones (3)
  • Gouty arthritis (4)
  • High uric acid cardiovascular (5)
  • Uric acid connective calcification (6)
  • Sodium urate coronary artery calcification (7)
  • Crystal dissolution of calcium pyrophosphate (8)
  • Dissolve calcium oxalate crystal (9)

Not suitable for: Joints with severe deformity or even disabled

Application: Apply onto affected joints 3 to 5 times a day

Gentle reminder:

  • Avoid high purine food and drink, eat less fried and roasted food
  • Rest more and drink more water

Outcome: Joints may become slightly relaxed in about 5 to 10 days

Recommendation:

  • Suggested treatment course is about 1-3 months, depending on individual's condition. May stop upon attaining satisfactory results.
  • If there is no positive progress during the 2 weeks trial, suggest to stop using and seek medical advice.

Potassium Bicarbonate Side Effects:

  1. If allergic or adverse reaction occurs, please stop using and seek medical advice immediately

Caution:

  • This product is a topical cream and cannot replace medicine
  • Not suitable if allergic to Potassium Bicarbonate
  • For serious or complicated health condition, please seek doctor's advice before using
  • If you do not understand the cause of your health condition or the issue persists, please consult your doctor as soon as possible

Ingredients: Body Lotion Base, Chondroitin sulfate (1), plant saponins, root extract, potassium citrate (2), Tripotassium citrate, potassium bicarbonate, chlorogenic acid, coffee tannic acid, pirilex fruit extract (3), sodium l-polyaspartate, sodium octanesulfonate, sodium tripolyphosphate, sodium polyphosphate

Specification: 60ml per bottle

Storage: Please store in a cool and dry place

Origin: Hong Kong, China

If you have a medical condition, please follow your doctor's medical treatment plan. Do consult your medical doctor before using the Multidisciplinary Rehabilitation Program (MRP). Please do not proceed if your medical doctor does not recommend the use of our MRP. If you'd like to seek a second opinion from other doctors, you may contact our online "Doctors Without Border", or other professional doctors at your convenience.

__


參考研究資料 / Ref:

  1. Eric W Orlowsky, Thomas V Stabler, Eulàlia Montell, Josep Vergés, and Virginia Byers Kraus. Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis. BMC Musculoskelet Disord. 2014; 15: 318. Published online 2014 Sep 27. doi: 10.1186/1471-2474-15-318. PMCID: PMC4189145. PMID: 25261974
  2. Zhao-Qing Meng, Zhao-Hui Tang, Yun-Xia Yan, Chang-Run Guo. Study on the Anti-Gout Activity of Chlorogenic Acid: Improvement on Hyperuricemia and Gouty Inflammation. November 2014, The American Journal of Chinese Medicine 42(06):1-13. DOI: 10.1142/S0192415X1450092X
  3. CHARLES Y. C. PAK, KHASHAYAR SAKHAEE, and CINDY FULLER. Successful management of uric acid nephrolithiasis withpotassium citrate. Section on Mineral Metabolism, Department of Internal Medicine, Southwestern Medical School, University of Texas Health Science Centerat Dallas, TX 75235. Kidney international, Vol. 30 (1986), pp. 422—428
  4. Qi Zhou, Shumin Liu,1 Donghua Yua, and Ning Zhang. Therapeutic Effect of Total Saponins from Dioscorea nipponica Makino on Gouty Arthritis Based on the NF-κB Signal Pathway: An In vitro Study. Journal List. Pharmacogn Mag. v.12(47); Jul-Sep 2016. PMC4989800. Pharmacogn Mag. 2016 Jul-Sep; 12(47): 235–240. doi: 10.4103/0973-1296.186344. PMCID: PMC4989800. PMID: 27601855
  5. Angelo L Gaffo,1 N Lawrence Edwards,2 and Kenneth G Saag. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Journal List.Arthritis Res Ther. v.11(4); 2009.PMC2745789. Arthritis Res Ther. 2009; 11(4): 240. Published online 2009 Aug 19. doi: 10.1186/ar2761. PMCID: PMC2745789. PMID: 19725932
  6. W Mohr 1 , E Görz. [Mixed tophi. Calcium pyrophosphate dihydrate crystals in gout tophi]. Z Rheumatol. 2000 Aug;59(4):240-4. doi: 10.1007/s003930070066. PMID: 11013985. DOI: 10.1007/s003930070066
  7. Mariano Andres,1Marıa-Amparo Quintanilla,2Francisca Sivera,2JoseSanchez-Paya,3Eliseo Pascual,4Paloma Vela,4and Juan-Miguel Ruiz-Nodar3. Silent Monosodium Urate Crystal Deposits Are AssociatedWith Severe Coronary Calcification inAsymptomatic Hyperuricemia. An Exploratory Study. ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 6, June 2016, pp 1531–1539DOI 10.1002/art.39581
  8. R Cinia, D Chindamob, M Catenacciob, S Lorenzinib, E Selvib, F Neruccib, M P Picchib, G Bertib, R Marcolongob. Dissolution of calcium pyrophosphate crystals by polyphosphates: an in vitro and ex vivo study. http://dx.doi.org/10.1136/ard.60.10.962
  9. Shouwu Guo, Michael D. Ward, Jeffrey A. Wesson. Direct Visualization of Calcium Oxalate Monohydrate Crystallization and Dissolution with Atomic Force Microscopy and the Role of Polymeric Additives. Langmuir 2002, 18, 11, 4284–4291. Publication Date:May 1, 2002. https://doi.org/10.1021/la011754+


本品等並非根據《藥劑業及毒藥條例》或《中醫藥條例》注册。 任何對其提出的宣稱均不受此類登記評估的約束。 本產品不用於診斷、治療或預防任何疾病。

This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.
Save this product for later